(Breast Cancer) DS-8201a at ESMO 2016
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
- October 28, 2016
- Reading time: 1 minute
At ESMO 2016, Dr. Kenji Tamura of the National Cancer Center Hospital Japan presented results demonstrating that DS-8201a — an anti-HER2 antibody-drug conjugate — showed efficacy in breast cancer and gastric cancer. DS-8201a is a compound that links an anti-HER2 antibody with DXd, a topoisomerase inhibitor. In animal models, it demonstrated activity even in tumors resistant to T-DM1 (ado-trastuzumab emtansine).
The drug has progressed to human clinical trials targeting breast cancer, gastric cancer, and gastroesophageal junction adenocarcinoma patients in a Phase 1 study administered every three weeks. Phase 1 consisted of toxicity testing with gradual dose escalation, enrolling Japanese and American patients, with subgroups including low-HER2 patients and solid tumor patients other than breast or gastric cancer. At the time of this presentation, Phase 1 data from 22 of 23 enrolled patients (median age 66 years) was reported: 16 breast cancer patients (73%), 5 gastric cancer patients (23%), and 1 GEJ adenocarcinoma patient (5%).
Dose levels tested: 0.8, 1.6, 3.2, 6.4, and 8.0 mg/kg. Three patients received 8.0 mg/kg, of whom two subsequently had their dose reduced.
Safety results: No Grade 4 adverse events or life-threatening events were observed. Seven Grade 3 adverse events occurred: hypocalcemia, anemia, lymphopenia, and cholangitis. All participants completed subsequent treatment cycles without discontinuation due to adverse events.
Efficacy results: Among 20 evaluable patients (12 previously treated with T-DM1, 5 with low HER2 expression), 7 achieved partial response (PR), with a disease control rate (DCR) of 90%. Among prior T-DM1 recipients, the response rate was 18% and DCR was 64%. With continued DS-8201a treatment, the response rate was 42% and DCR was 92%. All PR patients received doses of 5.4 mg/kg or higher.
An expansion cohort at 6.4 mg/kg every three weeks is currently ongoing.
Tags: #BreastCancer #GastricCancer
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4